Supernus Pharmaceuticals | SUPN - Current Liabilities



Supernus Pharmaceuticals reported $286.36M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Abbott USD 13.44B 435M Jun/2025
ANI Pharmaceuticals USD 236.83M 35.02M Jun/2025
Aurora Cannabis CAD 156.88M 7.07M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Canopy Growth CAD 98.67M 1.65M Jun/2025
Corcept Therapeutics USD 144.66M 1.6M Jun/2025
Eisai JPY 411.61B 39.31B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Novo Nordisk 207.52B 28.6B Jun/2025
Pacira USD 313.16M 1.57M Jun/2025
Perrigo USD 1.13B 52.3M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Supernus Pharmaceuticals USD 286.36M 4.59M Jun/2025
United Therapeutics USD 527.1M 194.4M Jun/2025
Xeris Pharmaceuticals USD 95.17M 5.27M Jun/2025